Amgen’s Kyprolis demonstrates survival benefits for multiple myeloma

Amgen has announced new clinical trial data that demonstrates the survival benefits offered by a new dose of its multiple myeloma therapy Kyprolis.

Topline results from the phase III ARROW trial showed that a once-weekly dose of Kyprolis plus dexamethasone allowed relapsed and refractory multiple myeloma patients to live 3.6 months longer without their disease worsening than a twice-weekly dose of Kyprolis.

The overall safety profile of the once-weekly regimen was also shown to be comparable to the more frequent dosing option, with a total of 478 patients involved in the study across around 100 sites worldwide.

These findings underline Kyprolis' status as the most effective proteasome inhibitor available to patients with multiple myeloma.

Dr Sean Harper, executive vice-president of research and development at Amgen, said: "We are encouraged by the efficacy and safety profile of Kyprolis and dexamethasone administered once-weekly in the ARROW study."

The drug has been shown to block proteasomes, leading to an excessive build-up of proteins within cells that can help to combat tumour tissue.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.